New Weight Loss Pill Approved for Use in the UK: What You Need to Know

The United Kingdom has approved a new oral weight-loss medicine that could significantly change how some people approach medical weight management. On 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved a tablet form of semaglutide, marketed as Wegovy, making it the UK's first GLP-1 receptor agonist tablet specifically approved for weight loss and weight management.

The decision is significant because semaglutide has already become widely known through injectable weight-management treatments. The newly approved tablet provides another option for eligible adults who may prefer an oral medicine rather than an injection.

However, the approval does not mean that everyone seeking to lose weight can simply obtain the medicine. It is a prescription treatment, and its use should be determined by an appropriate healthcare professional.

What Is the New Weight Loss Pill?

The newly approved tablet contains semaglutide, the same active ingredient used in Wegovy injections. It belongs to a group of medicines known as GLP-1 receptor agonists.

GLP-1 is a naturally occurring hormone involved in appetite regulation and digestion. Semaglutide mimics some of its effects, helping people feel fuller for longer and reducing hunger and food cravings.

According to the MHRA, the tablet is approved for adults with obesity, defined in the approval as a body mass index (BMI) of 30 or above. It can also be prescribed for adults who are overweight, with a BMI between 27 and 30, when they have at least one weight-related health condition.

The medicine is intended to be used alongside a reduced-calorie diet and increased physical activity.

How Does the Tablet Work?

The main purpose of semaglutide is to influence appetite rather than simply act as a traditional slimming product.

By activating GLP-1 receptors, semaglutide can affect areas of the brain involved in appetite control. People may experience reduced hunger and fewer food cravings, which can make it easier to consume fewer calories.

This is an important distinction. The medicine is not intended to replace healthy eating or physical activity. Instead, it is a medical treatment designed to support weight management as part of a broader approach.

The approval therefore represents a change in the available delivery method rather than a replacement for lifestyle measures.

A New Alternative to Weight Loss Injections

Perhaps the most important attraction of the new medicine is that it is taken as a tablet rather than administered by injection.

For some patients, injections can create anxiety, inconvenience or reluctance. An oral treatment may therefore make medical weight management more acceptable to people who do not want to use injectable medication.

The availability of an oral GLP-1 medicine could also increase public interest in medically supervised weight management.

Nevertheless, taking a tablet does not make the treatment risk-free. It remains a prescription medicine and should be used according to professional medical advice.

How Is the Dose Increased?

The MHRA states that the tablet begins at a dose of 1.5 mg once daily. The dose is then increased to 4 mg, 9 mg and eventually 25 mg, with a minimum of one month at each dose level.

This gradual increase is designed to allow the body to adjust to the medicine.

Patients should not attempt to accelerate the dosing schedule in an effort to lose weight more quickly. The UK's medicines regulator has specifically warned people against increasing doses beyond medical instructions.

Following the prescribed schedule is particularly important because side effects can occur during treatment.

What Are the Possible Side Effects?

Like other medicines, semaglutide can cause side effects.

The MHRA identifies gastrointestinal problems among the most common side effects. These include nausea, diarrhoea, constipation and vomiting.

The severity and duration of side effects can vary between individuals. Anyone experiencing concerning or persistent symptoms should speak with their doctor, pharmacist or nurse.

Patients should also tell healthcare professionals about other medicines they are taking and any relevant medical conditions before starting treatment.

Is the New Tablet Available on the NHS?

This is an important point that could easily be misunderstood.

Although the MHRA has approved the tablet for use in the UK, the medicine was not immediately available through the NHS following the June approval. The government stated that NHS use would be subject to established processes, including evaluation by the National Institute for Health and Care Excellence (NICE).

Therefore, regulatory approval and NHS availability are not the same thing.

A medicine can receive marketing authorisation because regulators have determined that its quality, safety and effectiveness meet required standards, while separate decisions determine whether and how it will be funded and provided through the NHS.

Beware of Fake Weight Loss Medicines

The growing popularity of GLP-1 medicines has also attracted illegal sellers.

The MHRA has warned consumers about purchasing weight-loss medicines through unregulated websites and social-media sellers. Counterfeit medicines can contain incorrect doses, unexpected ingredients or contaminants and may pose serious health risks.

People should therefore avoid purchasing prescription weight-loss medicines from unofficial sources.

A legitimate treatment should involve an appropriate medical assessment and prescription process.

What This Approval Means for the Future

The approval of the semaglutide tablet represents an important development in the UK's rapidly changing weight-management landscape.

It provides another medically regulated option for eligible adults and may be particularly attractive to people who prefer tablets to injections.

At the same time, the development highlights the need for responsible use. Weight-loss medicines are not ordinary diet products, and they should not be treated as quick fixes.

The UK's regulator continues to monitor the safety and effectiveness of semaglutide.

Ultimately, the new tablet could become an important tool in the treatment of obesity, but its benefits need to be considered alongside potential side effects, eligibility requirements, medical supervision and the importance of long-term lifestyle changes.

For people considering the treatment, the safest approach is straightforward: speak with a qualified healthcare professional, use only legitimate prescription channels, follow the prescribed dose and avoid promises of instant weight loss.

The UK's first approved GLP-1 weight-loss tablet may offer a new choice—but responsible medical use remains just as important as the medicine itself.